Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | JBJ-04-125-02 |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
JBJ-04-125-02 is a next-generation allosteric EGFR inhibitor, which selectively inhibits the kinase activity and activation of EGFR L858R, resulting in reduced cell proliferation, increased apoptosis and tumor growth inhibition (PMID: 31092401). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cetuximab + JBJ-04-125-02 | Cetuximab JBJ-04-125-02 | 0 | 0 |
| JBJ-04-125-02 | JBJ-04-125-02 | 0 | 0 |
| JBJ-04-125-02 + Mavelertinib | JBJ-04-125-02 Mavelertinib | 0 | 0 |
| JBJ-04-125-02 + Naquotinib | JBJ-04-125-02 Naquotinib | 0 | 0 |
| JBJ-04-125-02 + Osimertinib | JBJ-04-125-02 Osimertinib | 0 | 0 |